New Therapeutic Options for Advanced Hepatocellular Carcinoma

A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy

BACKGROUND & AIMS Hepatic arterial infusion chemotherapy (HAIC) is an option for treating advanced hepatocellular carcinoma (HCC). Because of the poor prognosis in HAIC non-responders, it is important to identify patients who may benefit from continuous HAIC treatment; however, there are currently no therapeutic assessment scores for this identification. Therefore, we aimed to establish a new t...

New and emerging therapeutic options for thyroid carcinoma.

The incidence of thyroid cancer has increased in the past few decades. Most patients with follicular cell–derived tumors present with well-differentiated carcinomas, and they have an excellent prognosis following treatment. Between 10% and 15% of tumors will mutate into more aggressive variants, such as tall-cell carcinoma and insular carcinoma. Some patients will present with poorly differenti...

Erlotinib for advanced hepatocellular carcinoma

OBJECTIVES To evaluate the efficacy and safety of erlotinib for the treatment of advanced hepatocellular carcinoma (HCC). METHODS A systematic literature search was undertaken in June 2015. Phase II/III trials of erlotinib for the treatment of advanced HCC were included. A descriptive analysis was applied. The study was conducted in College of Medicine, Honghui Hospital, Xi'an Jiaotong Univer...

Medical Management Options for Hepatocellular Carcinoma

Merkel Cell Carcinoma: Chemotherapy and Emerging New Therapeutic Options

Merkel cell carcinoma (MCC) is a rare neuroendocrine skin tumor that typically occurs in elderly, immunosuppressed patients. Infection with Merkel cell virus (MCV) and immunosuppression play an important role in the development of MCC. Different staging systems make it difficult to compare the existing clinical data. Furthermore, there predominantly exist single case reports and case series, bu...